Insulin containers in the packaging unit - IA site - BeijingOur Focus
Our diabetes, cardiovascular diseases, and transplant products contribute for one-third to Sanofi revenues.
Our Goals
We aim to reverse the course of chronic disease in the millions of people we serve by 2030. That’s why we partner with entrepreneurial companies that are pioneering new possibilities. We make science led investments in first and/or best-in-class assets in areas of high unmet needs
Partnering Success Stories
Provention Bio
After initially entering a U.S. commercialization and option agreement with them, we acquired Provention Bio, Inc. in 2023. In November 2022, the U.S. Food and Drug Administration approved Provention’s Tzield (teplizumab-mzwv) injection to delay the onset of stage 3 type 1 diabetes in patients aged eight years and older who currently have stage 2 type 1 diabetes. This first-in-class therapy for certain at-risk patients will now be a core asset of Sanofi’s General Medicines portfolio.
BioCorp
We collaborate with BioCorp to design, develop, and distribute a connected cap that clips onto SoloStar™ pre-filled insulin pens. The cap collects and adapts insulin doses to help people with diabetes optimize their daily treatment.
Kadmon
We acquired Kadmon to deliver transformative therapies. With Belumosudil in our transplant portfolio, we can help people with chronic graft versus host disease (GVHD). This approved, first-in-class treatment is designed for people over the age of 12 years who have failed at least two prior lines of systemic therapy.
Health2Sync
We collaborate with Taiwanese company Health2Sync to help people with diabetes manage their insulin. A regional digital platform offers a patient app and population-health tools for HCPs. It’s a flexible approach to realizing a connected care ecosystem.
Your Partnering Lead in General Medicines
For more information, contact our Business development team
Matthieu Merlin
Global Head of Business Development, General Medicines